Edgewise Therapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview

Edgewise Therapeutics

30/10/2023 18:31

* Edgewise Therapeutics Inc  EWTX.OQ   EWTX.O  is expected
to show
no change in quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for Edgewise
Therapeutics Inc
is for a loss of 40 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Edgewise
Therapeutics Inc is $27​, above​ its last closing price
of $6.25. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.40       -0.40      -0.34     Beat    14.6
 Mar. 31 2023  -0.35       -0.36      -0.36     Met     0
 Dec. 31 2022  -0.34       -0.34      -0.31     Beat    7.7​
 Sep. 30 2022  -0.35       -0.36      -0.34     Beat    4.5
 ​​Jun.        -0.33       -0.32      -0.32     Met     1.2
 30 2022                                                
 Mar. 31 2022  -0.28       -0.28      -0.30     Missed  -7.9​
 Dec. 31 2021  -0.24       -0.25      -0.26     Missed  -5.1
 Sep. 30 2021  -0.24       -0.22      -0.26     Missed  -16.4
 This summary was machine generated October 30 at 18:31 GMT.  All
figures in US dollars  unless otherwise stated